Peter Hersey

Research interests

Publications

• Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial

  The Lancet Oncology · 2021 · https://doi.org/10.1016/s1470-2045(21)00065-6

• Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz011

• CD103+ Tumor-Resident CD8+ T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti–PD-1 Treatment

  Clinical Cancer Research · 2018 · https://doi.org/10.1158/1078-0432.ccr-17-2257

• Whole-genome landscapes of major melanoma subtypes

  Nature · 2017 · https://doi.org/10.1038/nature22071

• Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1613210

• Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2017.75.6270

• Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

  JAMA · 2016 · https://doi.org/10.1001/jama.2016.4059

• Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

  Journal of Clinical Oncology · 2016 · 10.1200/jco.2015.64.0391

• Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma

  Journal of Clinical Oncology · 2016 · 10.1200/jco.2016.67.2477

• PD ‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐ PD ‐1/ PD ‐ L 1 clinical trials

  Pigment Cell & Melanoma Research · 2014 · https://doi.org/10.1111/pcmr.12340

• Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

  New England Journal of Medicine · 2013 · https://doi.org/10.1056/nejmoa1305133

• Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

  New England Journal of Medicine · 2012 · https://doi.org/10.1056/nejmoa1112302

• Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

  New England Journal of Medicine · 2012 · https://doi.org/10.1056/nejmoa1203421

• Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group

  Zurich Open Repository and Archive (University of Zurich) · 2012 · 10.5167/uzh-63198

• Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma

  Clinical Cancer Research · 2011 · 10.1158/1078-0432.ccr-11-2479

• Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

  Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2007.15.7636

• Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group

  Journal of Clinical Oncology · 2006 · https://doi.org/10.1200/jco.2006.06.0483

Current projects

No projects listed.